Brought to you by 
Merz, NTI, Children's sign deal, modify terms
13 Jun 2017
Executive Summary
German pharma company Merz licensed rights to an NMDA antagonist, memantine, from Children's Hospital of Boston, and signed an R&D agreement with Neurobiological Technologies Inc.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merz, NTI, Children's sign deal, modify terms
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice